Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Neurocrine Biosciences (NBIX) EBITDA Margin (2017 - 2025)

Neurocrine Biosciences' EBITDA Margin history spans 15 years, with the latest figure at 19.07% for Q4 2025.

  • For Q4 2025, EBITDA Margin rose 403.0% year-over-year to 19.07%; the TTM value through Dec 2025 reached 16.99%, up 255.0%, while the annual FY2025 figure was 16.99%, 255.0% up from the prior year.
  • EBITDA Margin reached 19.07% in Q4 2025 per NBIX's latest filing, down from 26.44% in the prior quarter.
  • In the past five years, EBITDA Margin ranged from a high of 142.42% in Q4 2021 to a low of 99.0% in Q2 2022.
  • Average EBITDA Margin over 5 years is 14.62%, with a median of 15.59% recorded in 2024.
  • Peak YoY movement for EBITDA Margin: plummeted -11934bps in 2022, then soared 12045bps in 2023.
  • A 5-year view of EBITDA Margin shows it stood at 142.42% in 2021, then tumbled by -84bps to 23.08% in 2022, then skyrocketed by 32bps to 30.36% in 2023, then tumbled by -50bps to 15.04% in 2024, then grew by 27bps to 19.07% in 2025.
  • Per Business Quant, the three most recent readings for NBIX's EBITDA Margin are 19.07% (Q4 2025), 26.44% (Q3 2025), and 16.15% (Q2 2025).